Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Kasi, Pashtoon M ^a   Tawbi, Hussein A ^b   Oddis, Chester V ^c   Kulkarni, Hrishikesh S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BRONCHODILATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; FLUDARABINE; GLUCOCORTICOID; MITOXANTRONE; OXYGEN; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE RESPIRATORY FAILURE; ALLERGIC PNEUMONITIS; ALLERGIC REACTION; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ASTHMATIC STATE; B CELL LYMPHOMA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN INFARCTION; BRAIN ISCHEMIA; BRONCHIOLITIS OBLITERANS; BULLOUS SKIN DISEASE; CARDIOGENIC SHOCK; CHICKENPOX; CLINICAL FEATURE; COLITIS; CONNECTIVE TISSUE DISEASE; CONVULSION; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FOLLICULAR LYMPHOMA; GASTROENTERITIS; GRANULOCYTOPENIA; HEART FAILURE; HEART INFARCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TAMPONADE; HEPATITIS B; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERSTITIAL LUNG DISEASE; INTESTINE OBSTRUCTION; KIDNEY DYSFUNCTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LICHENOID ERUPTION; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYOCARDITIS; NEUTROPENIA; PARANEOPLASTIC PEMPHIGUS; PNEUMONIA; POSTMARKETING SURVEILLANCE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PYELONEPHRITIS; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SKIN LYMPHOMA; STEVENS JOHNSON SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; TUMOR LYSIS SYNDROME; URTICARIA; VASCULITIS; VIRUS INFECTION; WOUND INFECTION;

ANTINEOPLASTIC AGENTS; CRITICAL CARE; HUMANS; IMMUNOLOGIC FACTORS; RITUXIMAB;

EID: 84866178458     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11304     Document Type: Review

References (70)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007, 25:209-216. 10.1200/JCO.2006.09.0803, 17210942.
2. Aggarwal S. Targeted cancer therapies. Nat Rev Drug Discov 2010, 9:427-428. 10.1038/nrd3186, 20514063.
3. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, CD008794.
4. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675-1682. 10.1093/annonc/mdi320, 16030029.
5. Van Allen EM, Miyake T, Gunn N, Behler CM, Kohlwes J. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 2011, 7:76-79. 10.1200/JOP.2010.000042, 3051865, 21731512.
6. Rituximab Adverse Events and Side Effects Reported to the FDA (AERS). , http://www.drugcite.com/?q=rituximab
7. Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 2009, 17:91-98. 10.1007/s00520-008-0474-5, 18592276.
8. Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 2008, 16:393-398. 10.1007/s00520-007-0329-5, 17909865.
9. Rituximab Package Insert (Biogen Idec Inc., and Genentech, Inc.). , http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103705s5344lbl.pdf
10. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007, 3:86-95. 10.1038/ncprheum0424, 17299446.
11. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29(1 Suppl 2):2-9.
12. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6(5 Pt 1):859-866.
13. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
14. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, . REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025, 16947627, REFLEX Trial Group.
15. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U, . East German Study Group Hematology and Oncology Study Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007, 25:1986-1992. 10.1200/JCO.2006.06.4618, 17420513, East German Study Group Hematology and Oncology Study.
16. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008, 13:725-732. 10.1634/theoncologist.2008-0012, 18586928.
17. Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM. Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med 2006, 32:93-99. 10.1007/s00134-005-2836-5, 16308681.
18. Yang B, Lu XC, Yu RL, Chi XH, Zhang WY, Zhu HL, Yuan J, Zhao P. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci 2012, 343:337-341. 10.1097/MAJ.0b013e318244db6f, 22270402.
19. Darmon M, Thiery G, Ciroldi M, de Miranda S, Galicier L, Raffoux E, Le Gall JR, Schlemmer B, Azoulay E. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 2005, 33:2488-2493. 10.1097/01.CCM.0000181728.13354.0A, 16276171.
20. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005, 78:275-280. 10.1002/ajh.20276, 15795920.
21. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, . German PTLD Study Group; European PTLD Network Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012, 13:196-206. 10.1016/S1470-2045(11)70300-X, 22173060, German PTLD Study Group; European PTLD Network.
22. Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol 2012, 5:134-140. 10.1159/000337577, 3364040, 22666201.
23. Kang HJ, Park JS, Kim DW, Lee J, Jeong YJ, Choi SM, Lee SM, Yang SC, Yoo CG, Kim YW, Han SK, Yim JJ. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir Med 2012, 106:443-450. 10.1016/j.rmed.2011.11.009, 22154502.
24. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012, 40:641-648. 10.1183/09031936.00163911, 22282550.
25. Kulkarni HS, Aggarwal R. Successful treatment of acute respiratory failure using rituximab and cyclophosphamide as a combination immunosuppressive regimen in a ventilator-dependent patient having antisynthetase syndrome. Am J Respir Crit Care Med 2011, 183:A5661.
26. Pottier V, Pierrot M, Subra JF, Mercat A, Kouatchet A, Parrot A, Augusto JF. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus 2011, 20:656-659. 10.1177/0961203310386276, 21335399.
27. Pinto LF, Candia L, Garcia P, Marín JI, Pachón I, Espinoza LR, Marquez J. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab). Respiration 2009, 78:106-109. 10.1159/000156965, 18799870.
28. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, . RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232. 10.1056/NEJMoa0909905, 3137658, 20647199, RAVE-ITN Research Group.
29. Cartin-Ceba R, Fervenza FC, Specks U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 2012, 24:15-23. 10.1097/BOR.0b013e32834d5730, 22089095.
30. Ostensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, Brucato A, Tincani A. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008, 47(Suppl 3):iii28-31.
31. CTCAE-FAQ - Vocab_Wiki. , https://wiki.nci.nih.gov/display/VKC/Common+Terminology+Criteria+for+Adverse+Events+FAQ
32. Reporting serious problems to the FDA > what is a serious adverse event?. , http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
33. Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W. Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Dtsch Med Wochenschr 2002, 127:2253-2258. In German, 10.1055/s-2002-35017, 12397539.
34. Herold M, Ströhl J, Aßmann M, Eschenburg H, Franke A, Freund M, von Grünhagen U, Hahnfeld S, Hoffmann FA, Huhn D, Klinkenstein C, Knauf W, Pasold R, Hurtz H-J, Steglich J, Wolf H. [Acute toxicity of mitoxantrone, chlorambucil and prednisolone (MCP) versus MCP plus rituximab in low-grade non-Hodgkin's lymphoma - Interim results of a phase III trial]. Onkologie 2000, 23:164-166. In German.
35. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908. 10.1002/art.23059, 18050221.
36. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, . DANCER Study Group The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400. 10.1002/art.21778, 16649186, DANCER Study Group.
37. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, . HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. 10.1056/NEJMoa0706383, 18272891, HERMES Trial Group.
38. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, . Type 1 Diabetes TrialNet Anti-CD20 Study Group Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152. 10.1056/NEJMoa0904452, 19940299, Type 1 Diabetes TrialNet Anti-CD20 Study Group.
39. Aviles A, Nambo MJ, Neri N, Cleto S, Castaneda C, Huerta-Guzman J, Murillo E, Contreras M, Talavera A, Gonzalez M. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma. Med Oncol 2007, 24:85-89. 10.1007/BF02685907, 17673816.
40. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
41. Seifert G, Reindl T, Lobitz S, Seeger K, Henze G. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. Haematologica 2006, 91(6 Suppl):ECR23.
42. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94:2217-2224.
43. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009, 124:722-728. 10.1002/ijc.23991, 18989899.
44. Tyden G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G, Wadstrom J, Gabel M, Mjornstedt L. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009, 87:1325-1329. 10.1097/TP.0b013e3181a235fd, 19424032.
45. Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W, . German Low-Grade Lymphoma Study Group The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009, 23:153-161. 10.1038/leu.2008.261, 18818699, German Low-Grade Lymphoma Study Group.
46. Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009, 43:101-105. 10.1038/bmt.2008.306, 18794865.
47. Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L, Rule SA. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leuk Lymphoma 2009, 50:211-215. 10.1080/10428190802688509, 19197729.
48. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463. 10.1200/JCO.2002.11.076, 12011122.
49. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60:1895-1905. 10.1002/art.24567, 19565475.
50. Bentdal OH, Froland SS, Larsen S. Cell-mediated immunity in anorexia nervosa augmented lymphocyte transformation response to concanavalin A and lack of increased risk of infection. Clin Nutr 1989, 8:253-258. 10.1016/0261-5614(89)90035-6, 16837297.
51. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989, 32:837-843.
52. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, . MabThera International Trial Group CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391. 10.1016/S1470-2045(06)70664-7, 16648042, MabThera International Trial Group.
53. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312. 10.1080/10428190701411441, 17613758.
54. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012, 29:1237-1241. 10.1007/s12032-011-9974-0, 21556931.
55. Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 2006, 10:211. 10.1186/cc4907, 1550893, 16677413.
56. Cairo MS, Coiffier B, Reiter A, Younes A, . TLS Expert Panel Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010, 149:578-586. 10.1111/j.1365-2141.2010.08143.x, 20331465, TLS Expert Panel.
57. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242. 10.1056/NEJMoa011795, 11807147.
58. Ghielmini M, Schmitz SF, Bürki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000, 11(Suppl 1):123-126. 10.1093/annonc/11.suppl_1.S123, 11079129.
59. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992. 10.1200/JCO.2005.08.133, 15668467.
60. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423. 10.1182/blood-2003-10-3411, 14976046.
61. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005, 45:1481-1486. 10.1111/j.1537-2995.2005.00560.x, 16131381.
62. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006, 24:234-237. 10.1002/hon.799, 16948177.
63. Tonelli AR, Lottenberg R, Allan RW, Sriram PS. Rituximab-induced hypersensitivity pneumonitis. Respiration 2009, 78:225-229. 10.1159/000163069, 2790794, 18843175.
64. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008, 76:449-453. 10.1159/000104866, 17596682.
65. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, Wang SA. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012, 25:237-245.
66. Schellongowski P, Staudinger T, Kundi M, Laczika K, Locker GJ, Bojic A, Robak O, Fuhrmann V, Jäger U, Valent P, Sperr WR. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 2011, 96:231-237. 10.3324/haematol.2010.031583, 3031690, 21071501.
67. Cornejo A, Bohnenblust M, Harris C, Abrahamian GA. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. Cancer Chemother Pharmacol 2009, 64:857-860. 10.1007/s00280-009-1062-1, 19588139.
68. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840. 10.1182/blood-2008-10-186999, 2686134, 19264918.
69. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol 2005, 153:167-173. 10.1111/j.1365-2133.2005.06659.x, 16029344.
70. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J 2006, 12:3.